In-article:

Biophytis presents the development of Sarconeos (BIO101) in Phase 3 in the treatment of Sarcopenia at the 15th international SCWD congress – 06/27/2022 at 23:00


Paris, France, Cambridge (Massachusetts, United States), June 27, 2022 – 11:00 p.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a biotechnology company at the clinic specializing in the development of treatments that aim to slow the degenerative processes associated with aging and improve the functional results of patients suffering from age-related diseases, announces today that it is giving an oral presentation on the development of Sarconeos (BIO101) for the treatment of sarcopenia at the 15th SCWD (Society on Sarcopenia, Cachexia & Wasting disorders) international congress.

This oral presentation given by Drs. Waly Dioh and Cendrine Tourette and entitled: “BIO101 in development for the treatment of Sarcopenia” resumes the main stages of development of Sarconeos (BIO101) already reached, mainly the results of the Phase 2 study of SARA-INT, as well as the major Phase 3 lines that the Company intends to initiate before the end of 2022.

On the strength of the results of Phase 2 of SARA-INT and in the continuity of this, the Company has requested the scientific opinion of the European (EMA) and American (FDA) regulatory authorities in order to define the design and the start-up conditions. of phase 3 of the SARA program. Sarconeos (BIO101) has the potential to be the first drug candidate to enter Phase 3 in sarcopenia.



Source link -86